The massive CEO restricted stock grant and debt-for-equity swap concentrate voting control in Saadi at 90.9%, while the facility's $28.6M undrawn capacity and PIPE option create ongoing dilution risk. Monitor for stockholder approval requests to exceed the 19.99% issuance cap and for any PIPE activation if the stock reaches $500/share.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tevogen amended its $36M credit facility with The Patel Family LLP, extending the borrowing period to May 2029, setting a fixed $7.40/share price for share repayments, and repaying the $7.4M outstanding balance plus $177,880 interest with 1,023,733 shares. Separately, the CEO received 50M performance-vesting restricted shares requiring $1B revenue by 2031, increasing his voting power to 90.9%.
Key Financial Metrics
Key Facts
- Outstanding $7.4M loan principal plus $177,880 interest repaid with 1,023,733 shares at $7.40/share, eliminating all liabilities under the agreement
- CEO Ryan Saadi granted 50,000,000 restricted shares vesting only if Tevogen achieves $1.0B revenue by Dec 31, 2031; unvested shares carry voting rights
- Post-grant and repayment, Saadi holds ~90.9% voting power of 67,880,267 outstanding shares
- Credit facility extended to May 31, 2029 with $28.6M remaining available; up to ~4.99M additional shares may be issuable
- Activist SC 13D filings within 47 days of this 8-K signal potential forced strategic action
Financial Impact
$7.4M debt extinguished via 1,023,733 shares; up to $28.6M additional debt capacity with potential ~4.99M share dilution; CEO grant represents 73.6% of current outstanding shares
Risk Factors
- Extreme CEO voting control (90.9%) disenfranchises minority holders
- Up to ~4.99M additional shares issuable under the facility, diluting existing holders
- Activist filings within 47 days suggest potential forced strategic actions
- Revenue threshold of $1B by 2031 is extremely high for a pre-revenue biotech; restricted shares likely never vest
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-049649 |
| Document: form8-k.htm | 0001493152-26-049649 |
| Document: 0001493152-26-049649-index-headers.html | 0001493152-26-049649 |
| Document: 0001493152-26-049649-index.html | 0001493152-26-049649 |
| Document: 0001493152-26-049649.txt | 0001493152-26-049649 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | 8-K | $5.51 | awaiting T+60 | awaiting T+60 | $5.69 (+3.27%) |
Nov 2, 2026 1d ago | 8-K | $5.59 | awaiting T+60 | awaiting T+60 | $5.69 (−1.79%) |
Sep 30, 2026 4w ago | 8-K | $6.72 | awaiting T+60 | awaiting T+60 | $5.69 (−15.33%) |
Sep 16, 2026 6w ago | SC 13D/A | $7.71 | awaiting T+60 | awaiting T+60 | $5.69 (−26.20%) |
Sep 16, 2026 6w ago | SC 13D/A | $7.71 | awaiting T+60 | awaiting T+60 | $5.69 (−26.20%) |
Sep 16, 2026 6w ago | 8-K | $7.71 | awaiting T+60 | awaiting T+60 | $5.69 (−26.20%) |
Jun 26, 2026 18w ago | EFFECT | $7.00 $7.43 | ▼ −6.14% | ▼ −1.66% | $5.69 (+18.71%) |
Jun 12, 2026 20w ago | S-3 | $10.02 $7.34 | ▲ +26.75% | ▲ +27.75% | $5.69 (+43.21%) |
Jun 9, 2026 21w ago | Press Release | $10.75 $7.17 | ▼ −33.30% | ▼ −37.12% | $5.69 (−47.07%) |
May 28, 2026 22w ago | Press Release | $8.04 $6.75 | ▼ −16.04% | ▼ −17.78% | $5.69 (−29.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers